Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00483106|
Recruitment Status : Recruiting
First Posted : June 6, 2007
Last Update Posted : September 1, 2017
|Condition or disease||Intervention/treatment||Phase|
|Attention Deficit Hyperactivity Disorder||Drug: Ritalin Drug: Placebo||Phase 4|
Attention Deficit Hyperactivity disorder (ADHD) is a syndrome that is characterized by inattention, motor hyperactivity and impulsivity. It affects 8 to 12% of the population. The presentation of children with ADHD can be varied, from simple inattention to severe motor hyperactivity and impulsivity. It has a negative impact on the child's life, including poor school achievement and difficulty with peer and family relationships.
Although the etiology of ADHD is not well understood, genetic factors are known to play a significant role in the pathogenesis of ADHD, as indicated by family, twin and adoption studies. In addition, environmental factors such as smoking during pregnancy and obstetrical complications have been found to contribute significantly in increasing the risk for and severity of ADHD. It is therefore likely that genetic predisposing factors interact with environmental factors to produce the behavioral disturbances observed in ADHD. The first goal of this study is therefore to investigate possible genetic and environmental risk factors, and examine how they might interact to confer increased risk for ADHD.
A majority of children (70%) with ADHD show a significant improvement with of their behavioral disorder when treated with stimulant drugs such as methylphenidate (MPH). However, the extent to which each child benefits from MPH is variable and some of the children do not improve at all in spite of adequate trials with stimulant drugs. The second purpose of this project is to study the correlates/predictors of responsiveness to MPH in school-aged children and to identify genetic factors that may modulate the behavioral response to this drug.
In order to achieve our research goals, children with ADHD are invited to participate to a two-week double-blind placebo controlled medication trial with MPH (Ritalin, 0.5mg/kg/day). During these two weeks, neuropsychological and behavioral assessments of the child are performed at the clinic to evaluate the cognitive performance of the child while on medication and placebo. Parents are invited to answer questionnaires about the behavior of their child and about family history of mental disorders, as well as prenatal and perinatal risk factors. Finally, the participating child, both parents, and siblings are invited to provide a blood or saliva sample for genetic analysis.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1000 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Primary Purpose:||Basic Science|
|Official Title:||Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)|
|Study Start Date :||November 1999|
|Estimated Primary Completion Date :||September 2018|
|Estimated Study Completion Date :||March 2025|
|Placebo Comparator: Ritalin||
0.25 mg/kg bid, orally for 7 consecutive days
|Placebo Comparator: Placebo||
taken orally twice a day for 7 consecutive days
- Conners' Global Index - Parent Version (CGI-P) [ Time Frame: Once weekly during the medication trial ]10-item standardized scale evaluating ADHD symptoms; filled by parents.
- Conner's Global Index - Teacher Version (CGI-T) [ Time Frame: Once weekly during the medication trial ]10-item standardized scale evaluating ADHD symptoms; filled by teachers.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00483106
|Contact: Johanne Bellingham, RA||(514) 761-6131 ext email@example.com|
|Douglas Mental Health University Institute||Recruiting|
|Montreal, Quebec, Canada, H4H 1R3|
|Contact: Johanne Bellingham, RA (514) 761-6131 ext 2098 firstname.lastname@example.org|
|Principal Investigator:||Ridha Joober, MD, PhD||Douglas Mental Health University Institute|
|Principal Investigator:||Natalie Grizenko, MD, FRCPC||Douglas Mental Health University Institute|